Relationship Between OCT1 Expression and Poor Response to Sorafenib in HCC

Jesper Andersen, PhD
Published: Friday, Apr 21, 2017



Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the relationship between reduced organic cation transporter-1 (OCT1) and poor response to sorafenib (Nexavar) in hepatocellular carcinoma (HCC) and cholangiocarcinoma.

Overexpression of OCT1 in HCC and cholangiocarcinoma is related to an increase in uptake and sensitivity to sorafenib, according to recent results of a study.

Although, if a patient has endogenously induced tumors—either by a carcinogen or by modification in mouse models—there is a downregulation of OCT1, which leads to the poor pharmacological effect of sorafenib, says Andersen.
 


Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the relationship between reduced organic cation transporter-1 (OCT1) and poor response to sorafenib (Nexavar) in hepatocellular carcinoma (HCC) and cholangiocarcinoma.

Overexpression of OCT1 in HCC and cholangiocarcinoma is related to an increase in uptake and sensitivity to sorafenib, according to recent results of a study.

Although, if a patient has endogenously induced tumors—either by a carcinogen or by modification in mouse models—there is a downregulation of OCT1, which leads to the poor pharmacological effect of sorafenib, says Andersen.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x